ADAP
Price
$0.87
Change
-$0.00 (-0.00%)
Updated
Oct 16 closing price
20 days until earnings call
CLVLY
Price
$10.18
Change
-$0.00 (-0.00%)
Updated
Oct 4 closing price
Ad is loading...

ADAP vs CLVLY

Header iconADAP vs CLVLY Comparison
Open Charts ADAP vs CLVLYBanner chart's image
Adaptimmune Therapeutics
Price$0.87
Change-$0.00 (-0.00%)
Volume$1.13M
CapitalizationN/A
Clinuvel Pharmaceuticals
Price$10.18
Change-$0.00 (-0.00%)
Volume$1.12K
CapitalizationN/A
View a ticker or compare two or three
ADAP vs CLVLY Comparison Chart
Loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ADAP vs. CLVLY commentary
Oct 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a StrongSell and CLVLY is a Hold.

COMPARISON
Comparison
Oct 18, 2024
Stock price -- (ADAP: $0.84 vs. CLVLY: $9.45)
Brand notoriety: ADAP and CLVLY are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 75% vs. CLVLY: 59%
Market capitalization -- ADAP: $243.06M vs. CLVLY: $485.07M
ADAP [@Biotechnology] is valued at $243.06M. CLVLY’s [@Biotechnology] market capitalization is $485.07M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.89B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileCLVLY’s FA Score has 1 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • CLVLY’s FA Score: 1 green, 4 red.
According to our system of comparison, CLVLY is a better buy in the long-term than ADAP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 5 TA indicator(s) are bullish.

  • ADAP’s TA Score: 5 bullish, 3 bearish.

Price Growth

ADAP (@Biotechnology) experienced а -4.27% price change this week, while CLVLY (@Biotechnology) price change was -2.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

ADAP is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CLVLY($485M) has a higher market cap than ADAP($243M). ADAP YTD gains are higher at: 9.836 vs. CLVLY (-11.486). CLVLY has higher annual earnings (EBITDA): 56.3M vs. ADAP (-85.06M). ADAP has higher revenues than CLVLY: ADAP (141M) vs CLVLY (88.2M).
ADAPCLVLYADAP / CLVLY
Capitalization243M485M50%
EBITDA-85.06M56.3M-151%
Gain YTD9.836-11.486-86%
P/E RatioN/A19.70-
Revenue141M88.2M160%
Total Cash215MN/A-
Total Debt47.3MN/A-
FUNDAMENTALS RATINGS
ADAP vs CLVLY: Fundamental Ratings
ADAP
CLVLY
OUTLOOK RATING
1..100
5620
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9747
PRICE GROWTH RATING
1..100
6459
P/E GROWTH RATING
1..100
10088
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CLVLY's Valuation (3) in the null industry is somewhat better than the same rating for ADAP (36) in the Biotechnology industry. This means that CLVLY’s stock grew somewhat faster than ADAP’s over the last 12 months.

CLVLY's Profit vs Risk Rating (100) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that CLVLY’s stock grew similarly to ADAP’s over the last 12 months.

CLVLY's SMR Rating (47) in the null industry is somewhat better than the same rating for ADAP (97) in the Biotechnology industry. This means that CLVLY’s stock grew somewhat faster than ADAP’s over the last 12 months.

CLVLY's Price Growth Rating (59) in the null industry is in the same range as ADAP (64) in the Biotechnology industry. This means that CLVLY’s stock grew similarly to ADAP’s over the last 12 months.

CLVLY's P/E Growth Rating (88) in the null industry is in the same range as ADAP (100) in the Biotechnology industry. This means that CLVLY’s stock grew similarly to ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAP
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 14 days ago
83%
Declines
ODDS (%)
Bearish Trend 7 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
86%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ADAP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME21.660.39
+1.83%
GameStop Corp
BTC.X67612.720000571.609400
+0.85%
Bitcoin cryptocurrency
TSLA221.331.76
+0.80%
Tesla
SPY582.302.52
+0.43%
SPDR® S&P 500® ETF Trust
AAPL231.78-2.07
-0.89%
Apple

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with PSTX. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then PSTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-1.02%
PSTX - ADAP
36%
Loosely correlated
N/A
ENTA - ADAP
36%
Loosely correlated
+3.68%
ORMP - ADAP
36%
Loosely correlated
+3.40%
CYTK - ADAP
34%
Loosely correlated
-0.18%
NUVB - ADAP
33%
Poorly correlated
+10.30%
More

CLVLY and

Correlation & Price change

A.I.dvisor tells us that CLVLY and ADAP have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLVLY and ADAP's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLVLY
1D Price
Change %
CLVLY100%
N/A
ADAP - CLVLY
22%
Poorly correlated
-1.02%
QLGN - CLVLY
21%
Poorly correlated
-1.10%
ATNM - CLVLY
20%
Poorly correlated
-4.00%
CLVLF - CLVLY
20%
Poorly correlated
+0.64%
BSEM - CLVLY
11%
Poorly correlated
+0.67%
More